Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma - Results from the DIRECTOR trial

Neuro-Oncology

Volumn 18, Issue 4, 2016, Pages 549-556

  Suchorska, Bogdana ^a   Weller, Michael ^b   Tabatabai, Ghazaleh ^b,c   Senft, Christian ^d   Hau, Peter ^e   Sabel, Michael C ^f   Herrlinger, Ulrich ^g   Ketter, Ralf ^h   Schlegel, Uwe ⁱ   Marosi, Christine ^j   Reifenberger, Guido ^f   Wick, Wolfgang ^k   Tonn, Jörg C ^a   Wirsching, Hans Georg ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ RUHR UNIVERSITY BOCHUM   (Germany)

^j UNIVERSITY OF VIENNA   (Austria)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

DIRECTOR; outcome; re operation; recurrent GBM; volumetry

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REOPERATION; SURVIVAL TIME; TUMOR VOLUME; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEUROSURGERY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROSURGICAL PROCEDURES; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN; YOUNG ADULT;

EID: 84966589269     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov326     Document Type: Article

References (29)

1. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395-e403.
2. Stupp R, Mason WP, van den BentMJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
4. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100-1108.
5. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
6. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576; discussion 564-576.
7. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115(1):3-8.
8. Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013;24(12):3117-3123.
9. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
10. Hervey-Jumper SL, Berger MS. Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery. 2014;75(5):491-499; discussion 498-499.
11. Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma-are we there yet? Neurooncol. 2013;15(1):4-27.
12. Oppenlander ME, Wolf AB, Snyder LA, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg. 2014;120(4):846-853.
13. Weller M, Tabatabai G, Kastner B, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21(9): 2057-2064.
14. Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
15. Suchorska B, Jansen NL, Linn J, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015;84(7):710-719.
16. Passingham RE, Stephan KE, Kotter R. The anatomical basis of functional localization in the cortex. Nature reviews. Neuroscience. 2002;3(8):606-616.
17. Efficace F, Bottomley A. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer. 2002; 38(14):1824-1831.
18. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6): 1033-1040.
19. Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol. 2011;98(1):1-14.
20. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
21. Grabowski MM, Recinos PF, Nowacki AS, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115-1123.
22. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16(1): 113-122.
23. Park CK, Kim JH, Nam DH, et al. A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro Oncol. 2013;15(8):1096-1101.
24. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838-3843.
25. Nava F, Tramacere I, Fittipaldo A, et al. Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol. 2014;16(5):719-727.
26. Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011;13(10):1118-1124.
27. Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer. 2012;48(8):1176-1184.
28. Ringel F, Pape H, Sabel M, et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2016;18(1):96-104.
29. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg. 2012;117(6):1032-1038.